Food and Drug Administration Commissioner Scott Gottlieb says he’s concerned about how hospitals are being paid for custom-built cancer therapies, STAT reports.
Gottlieb said drug development could be negatively impacted by the paradigm.
“I’m extremely worried that if we don’t adapt the approach to reimbursement soon, we may foreclose the therapeutic opportunities,” Gottlieb said.
To read the full report on STAT, click here. (Paid subscription required)